ROLE OF IL-21 AND IL-27 IN COVID-19 PATIENTS RECEIVING CONVALESCENT PLASMA

Abstract

The presence of a cytokine storm in COVID-19 patients increases the severity of the disease and increases mortality. The administration of convalescent plasma therapy in COVID-19 patients is still the treatment of choice until now. The principle of convalescent plasma therapy is the transfer of passive antibodies so that they function as neutralizing antibodies against acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Convalescent plasma therapy has shown to reduce clinical symptoms to the recovery stage in COVID-19 patients. One of the targets of this therapy is to reduce the cytokine storm. The roles of IL-21 and IL27 in COVID-19 patients receiving convalescent plasma therapy have not studied in detail. Therefore, we will review the role of IL-21 and IL-27 in COVID-19 patients given convalescent plasma. The method used in collecting articles for the publication year 2020- 2021 uses the keywords “Interleukin-21”, “Interleukin-27”, “COVID-19” and “Convalescent plasma”. The results of the review described an increase in IL-21 associated with antibody production. While IL-27 is possible to increase the number of cytokines with its nature as an immunomodulator by Toll-Like Receptors.